These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15328420)

  • 1. BSR Biologics Registry.
    Griffiths I; Silman A; Symmons D; Scott DG
    Rheumatology (Oxford); 2004 Dec; 43(12):1463-4. PubMed ID: 15328420
    [No Abstract]   [Full Text] [Related]  

  • 2. The British Society for Rheumatology Biologics Register: 6 years on.
    Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
    Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Bruce ES; Kearsley-Fleet L; Watson KD; Symmons DP; Hyrich KL
    Rheumatology (Oxford); 2016 Jul; 55(7):1336-7. PubMed ID: 27118877
    [No Abstract]   [Full Text] [Related]  

  • 4. The British Society for Rheumatology biologics register.
    Watson K; Symmons D; Griffiths I; Silman A
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv42-3. PubMed ID: 16239385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study.
    Marshall NJ; Wilson G; Lapworth K; Kay LJ
    Rheumatology (Oxford); 2004 Aug; 43(8):1034-8. PubMed ID: 15150436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. British Society for Rheumatology Biologics Register.
    Silman A; Symmons D; Scott DG; Griffiths I
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii28-9. PubMed ID: 14532144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.
    Ding T; Ledingham J; Luqmani R; Westlake S; Hyrich K; Lunt M; Kiely P; Bukhari M; Abernethy R; Bosworth A; Ostor A; Gadsby K; McKenna F; Finney D; Dixey J; Deighton C; ;
    Rheumatology (Oxford); 2010 Nov; 49(11):2217-9. PubMed ID: 20837498
    [No Abstract]   [Full Text] [Related]  

  • 8. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Aug; 54(8):2701-2. PubMed ID: 16871549
    [No Abstract]   [Full Text] [Related]  

  • 9. Promoting science over serendipity in prescribing anti-TNF therapy.
    Chee MM; Alcorn N; Paterson K; Madhok R
    Rheumatology (Oxford); 2009 Aug; 48(8):865-6. PubMed ID: 19403738
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
    Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Safety of biologic therapy - results from the German biologics register RABBIT].
    Strangfeld A; Zink A
    Dtsch Med Wochenschr; 2014 Sep; 139(37):1817-20. PubMed ID: 25180996
    [No Abstract]   [Full Text] [Related]  

  • 13. Joint approach.
    Palmer K
    Minn Med; 2009 Sep; 92(9):22-5. PubMed ID: 19877473
    [No Abstract]   [Full Text] [Related]  

  • 14. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.
    Kay LJ; Griffiths ID;
    Rheumatology (Oxford); 2006 Nov; 45(11):1376-9. PubMed ID: 17040892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.
    Deighton C; Hyrich K; Ding T; Ledingham J; Lunt M; Luqmani R; Kiely P; Bukhari M; Abernethy R; Ostor A; Bosworth A; Gadsby K; McKenna F; Finney D; Dixey J;
    Rheumatology (Oxford); 2010 Jun; 49(6):1197-9. PubMed ID: 20308121
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessing the safety of new arthritis drugs: are we there yet?
    Suissa S
    J Rheumatol; 2008 Dec; 35(12):2295-7. PubMed ID: 19040315
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of Biologic Agents in Elderly Patients with Rheumatoid Arthritis.
    Murota A; Kaneko Y; Yamaoka K; Takeuchi T
    J Rheumatol; 2016 Nov; 43(11):1984-1988. PubMed ID: 27585685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Focusing on the use of biologics in rheumatoid arthritis].
    Devauchelle-Pensec V; Guellec D
    Rev Prat; 2015 May; 65(5):687-8. PubMed ID: 26165113
    [No Abstract]   [Full Text] [Related]  

  • 19. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment.
    Arkema EV; Feltelius N; Olsson T; Askling J;
    Ann Rheum Dis; 2014 Nov; 73(11):2061-2. PubMed ID: 25096786
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.